Fremanezumab may be efficacious for the prophylaxis of chronic migraine in individuals with comorbid migraine and moderate/moderate to severe depression.
The investigators sought to evaluate whether early-life traumatic experiences, stressful life events, and alexithymia are associated with chronic migraine and medication overuse headache.
Individuals with chronic vs episodic migraine may be more likely to experience chronic back pain, chronic pain, neck pain, anxiety, and depression.
Researchers deployed a survey to determine the extent of pain, psychiatric, endocrine, and neurologic comorbidities in patients with chronic or episodic migraine.
For patients with chronic migraine, onabotulinumtoxinA was shown to have a better outcome.
Both erenumab and fremanezumab are currently under review by the FDA for the treatment of migraine.
Acupressure is not a beneficial adjunctive therapy to sodium valproate for the treatment of chronic migraine with aura.
More targeted injection sites may improve efficacy and the overall patient experience in chronic migraine.
The majority of centers follow protocols for administration of onabotulinumtoxinA.
A growing body of research indicates a number of shared features between chronic migraine and temporomandibular disorders.
In chronic migraine and medication overuse, those who frequently relapse into overuse after withdrawal have a worse clinical and psychological profile than patients who relapse less frequently.
During headache, patients with chronic migraine had greater activity in the right anterior hypothalamic region than patients with episodic or no migraine.
The study found a strong link between chronic migraine and psychological symptoms and beliefs that contribute to disability.
Remote electrical stimulation appears to have similar efficacy to standard drug treatments, including triptans.
Patients with chronic migraine and comorbidities incur nearly 2 times the health care costs incurred by patients with migraine alone.
A larger percentage of participants receiving CBT plus amitriptyline reached a 50% reduction in migraine frequency during treatment compared with HE plus amitriptyline.
Recovery time varies depending on which class of medication the patient is overusing.
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
A 30% or greater decline in mean monthly moderate-to-severe headache days was met by 45.3 % (n=24) of patients treated with occipital nerve stimulation.
Patients in both groups were satisfied with their care.
Previous analysis showed that treatment reduced chronic migraine frequency.
Participants experienced a reduction in headache days as soon as 3 days post-treatment.
Treatment of chronic, but not episodic migraine with botulinum toxin has been added to the treatment guidelines.
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study
- Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure